MAIA Biotechnology, Inc. (MAIA): who owns it and who trades it
As of Nov 16, 2026, MAIA insiders reported 25 purchases worth $971K in the last 12 months. The largest buyer was Vlad Vitoc (CEO), with $293K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling MAIA Biotechnology
From the latest filingsOverall: more buying than selling. Funds, insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns MAIA
36 funds and institutions reported MAIA shares worth $19.4M at the end of Q2 2026, about 22% of the company. The largest holder is Solas Capital Management, LLC with 5.0%.
Funds and institutions (13F) 22%Everyone else 78%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Solas Capital Management, LLC | 3.03M | 5.00% | $4.4M | -29% |
| Alyeska Investment Group, L.P. | 2.50M | 4.12% | $3.6M | No change |
| Vanguard Capital Management LLC | 2.41M | 3.98% | $3.5M | +16% |
| 683 Capital Management, LLC | 1.07M | 1.76% | $1.5M | No change |
| Centric Wealth Management | 796,723 | 1.31% | $1.1M | No change |
| Cable Car Capital, LP | 514,583 | 0.85% | $741K | -21% |
| Geode Capital Management, LLC | 504,380 | 0.83% | $727K | +40% |
| Bleichroeder LP | 500,000 | 0.82% | $720K | No change |
| Renaissance Technologies LLC | 415,700 | 0.69% | $599K | New |
| BlackRock, Inc. | 403,011 | 0.66% | $580K | +215% |
| Vanguard Fiduciary Trust Co | 336,688 | 0.55% | $485K | +69% |
| State Street Corp | 201,750 | 0.33% | $291K | +45% |
| Bleakley Financial Group, LLC | 181,623 | 0.30% | $262K | New |
| Northern Trust Corp | 125,171 | 0.21% | $180K | +138% |
| Morgan Stanley | 104,017 | 0.17% | $150K | +651% |
| Bridgeway Capital Management, LLC | 76,000 | 0.13% | $109K | +111% |
| Two Sigma Investments, LP | 50,383 | 0.08% | $72.6K | New |
| Envestnet Asset Management Inc | 44,347 | 0.07% | $63.9K | New |
| Susquehanna International Group, LLP | 35,223 | 0.06% | $50.7K | New |
| Pvg Asset Management Corp | 34,135 | 0.06% | $49.2K | New |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, MAIA insiders reported $971K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | Vlad Vitoc | CEO | Purchase | 73,000 | $1.37 | $100K | Form 4 |
| Sep 10, 2026 | Ramiro Guerrero | Director | Purchase | 37,595 | $1.32 | $49.6K | Form 4 |
| Aug 28, 2026 | Ramiro Guerrero | Director | Purchase | 46,620 | $1.35 | $62.9K | Form 4 |
| Aug 27, 2026 | Ramiro Guerrero | Director | Purchase | 78,239 | $1.39 | $109K | Form 4 |
| Aug 26, 2026 | Ramiro Guerrero | Director | Purchase | 8,931 | $1.39 | $12.4K | Form 4 |
| Aug 24, 2026 | Ramiro Guerrero | Director | Purchase | 1,794 | $1.33 | $2.4K | Form 4 |
| Aug 20, 2026 | Ramiro Guerrero | Director | Purchase | 11,899 | $1.37 | $16.3K | Form 4 |
| Jun 1, 2026 | Vlad Vitoc | CEO | Purchase | 72,700 | $1.39 | $101K | Form 4 |
| Jun 1, 2026 | Stan Smith | Director | Purchase | 75,000 | $1.34 | $100K | Form 4 |
| Jun 1, 2026 | Sergei Gryaznov | Chief Scientific Officer | Purchase | 2,000 | $1.35 | $2.7K | Form 4 |
| Dec 22, 2025 | Stan Smith | Director | Purchase | 57,189 | $1.22 | $69.8K | Form 4 |
| Dec 22, 2025 | Steven M Chaouki | Director | Purchase | 40,849 | $1.22 | $49.8K | Form 4 |
| Dec 22, 2025 | Ngar Yee Louie | Director | Purchase | 81,699 | $1.22 | $99.7K | Form 4 |
| Dec 5, 2025 | Stan Smith | Director | Purchase | 4,580 | $1.20 | $5.5K | Form 4 |
| Dec 5, 2025 | Stan Smith | Director | Purchase | 4,580 | $1.19 | $5.5K | Form 4 |
| Nov 28, 2025 | Vlad Vitoc | CEO | Purchase | 50,000 | $1.14 | $57K | Form 4 |
| Nov 28, 2025 | Cristian Luput | Director | Purchase | 18,145 | $1.11 | $20.1K | Form 4 |
| Nov 26, 2025 | Vlad Vitoc | CEO | Purchase | 22,000 | $1.05 | $23.1K | Form 4 |
| Nov 26, 2025 | Cristian Luput | Director | Purchase | 20,000 | $1.08 | $21.6K | Form 4 |
| Nov 26, 2025 | Stan Smith | Director | Purchase | 15,000 | $1.04 | $15.6K | Form 4 |
| Nov 25, 2025 | Vlad Vitoc | CEO | Purchase | 10,500 | $0.97 | $10.2K | Form 4 |
| Nov 25, 2025 | Cristian Luput | Director | Purchase | 10,000 | $0.98 | $9.8K | Form 4 |
| Nov 25, 2025 | Stan Smith | Director | Purchase | 15,000 | $0.98 | $14.7K | Form 4 |
| Nov 24, 2025 | Stan Smith | Director | Purchase | 10,000 | $0.99 | $9.9K | Form 4 |
| Nov 21, 2025 | Vlad Vitoc | CEO | Purchase | 1,800 | $0.92 | $1.7K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Vlad Vitoc | Chief Executive Officer, Director, 10% owner | $293K | – | Sep 14, 2026 |
| Ramiro Guerrero | Director | $252K | – | Sep 10, 2026 |
| Stan Smith | Director | $221K | – | Jun 1, 2026 |
| Ngar Yee Louie | Director | $99.7K | – | Dec 22, 2025 |
| Cristian Luput | Director | $51.5K | – | Nov 28, 2025 |
| Steven M Chaouki | Director | $49.8K | – | Dec 22, 2025 |
| Sergei Gryaznov | Chief Scientific Officer | $2.7K | – | Jun 1, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MAIA short interest
Low short interest. 4.0% of MAIA shares are sold short: about 1 share in 25. Over the last 12 reports the number of shares short went down 13%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.45M MAIA shares were sold short, 4.0% of the shares outstanding, down 2.8% from the report before. At the average daily volume of 271,949 shares, buying them all back would take about 9.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.45M | 4.03% | -3% | 271,949 | 9.0 |
| Oct 15, 2026 | 2.52M | 4.15% | -6% | 435,444 | 5.8 |
| Sep 30, 2026 | 2.69M | 4.42% | +28% | 784,612 | 3.4 |
| Sep 15, 2026 | 2.10M | 3.45% | -11% | 569,371 | 3.7 |
| Aug 31, 2026 | 2.35M | 3.86% | -15% | 368,663 | 6.4 |
| Aug 14, 2026 | 2.75M | 4.52% | -10% | 339,800 | 8.1 |
| Jul 31, 2026 | 3.06M | 5.05% | +5% | 453,344 | 6.8 |
| Jul 15, 2026 | 2.92M | 4.81% | -14% | 714,050 | 4.1 |
| Jun 30, 2026 | 3.41M | 5.62% | +7% | 588,353 | 5.8 |
| Jun 15, 2026 | 3.18M | 5.24% | +8% | 1.42M | 2.2 |
| May 29, 2026 | 2.95M | 4.87% | +5% | 520,676 | 5.7 |
| May 15, 2026 | 2.82M | 4.65% | -11% | 566,881 | 5.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
MAIA Biotechnology company events
MAIA Biotechnology filed 17 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Oct 6, 2026.
- Oct 6, 2026AnnouncementShared information with investors. Filing
- May 22, 2026VoteReported shareholder vote results. Filing
- May 14, 2026AgreementEnded an important agreement. Filing
- Apr 16, 2026AnnouncementMAIA Biotechnology, Inc. issued a press release entitled “MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer” A copy of the press release is attached hereto as Exhibit… Filing
- Apr 8, 2026AnnouncementMAIA Biotechnology, Inc. issued a press release entitled “MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein… Filing
- Apr 2, 2026LeadershipThe Board of Directors of MAIA Biotechnology, Inc. approved one-time bonus payments of $312,610 to Vlad Vitoc, the Company’s Chief Executive Officer and $50,000 to Jeffrey Himmelreich, the Company’s Head of Finance, in consideration for their efforts in connection with the Company’s recent capital… Filing
- Mar 31, 2026AnnouncementMAIA Biotechnology, Inc. issued a press release entitled “MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by… Filing
- Mar 27, 2026AnnouncementReference is made to the disclosure under Item 7.01 above which is hereby incorporated in this Item 8.01 by reference. Filing
- Mar 4, 2026AgreementMAIA Biotechnology, Inc. entered into an underwriting agreement with Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC, pursuant to which the Company agreed to issue and sell in an underwritten public offering an aggregate of 20,000,000 shares of the Company’s common stock… Filing
- Feb 24, 2026AnnouncementMAIA Biotechnology, Inc. issued a 2026 Letter to Shareholders detailing the Company’s development pipeline. Filing
- Jan 20, 2026AnnouncementMAIA Biotechnology, Inc. issued a press release entitled “MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines 2026 Clinical Milestones and Growth Momentum” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Filing
- Jan 13, 2026AnnouncementReference is made to the disclosure under Item 7.01 above which is hereby incorporated in this Item 8.01 by reference. Filing
- Dec 17, 2025AgreementMAIA Biotechnology, Inc. entered into a Securities Purchase Agreement with certain accredited investors for the issuance and sale in a private placement of: (i) 1,053,751 shares of the Company’s common stock, par value $0.0001 per share, and (ii) warrants to purchase up to 1,053,751 shares of… Filing
- Dec 11, 2025AnnouncementMade another announcement. Filing
- Dec 10, 2025AnnouncementMAIA Biotechnology, Inc. issued a press release entitled “MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Filing
- Nov 21, 2025AnnouncementMAIA Biotechnology, Inc. issued a press release entitled “MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Filing
- Nov 20, 2025AnnouncementMAIA Biotechnology, Inc. issued a press release entitled “MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
MAIA Biotechnology financials
Famous investors that hold MAIA
3 of the 50 well-known investors we track reported holding MAIA in their latest 13F filing. The largest position is Jim Simons's, worth $471K.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 399,100 | $471K | 0.0% | -4% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 226,877 | $268K | 0.0% | +812% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 17,175 | $20.3K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about MAIA Biotechnology, Inc. (MAIA) stock
Who owns the most MAIA stock?
The largest reported owner of MAIA Biotechnology, Inc. (MAIA) is Solas Capital Management, LLC, with 5.0% of the company. In total, 36 funds and institutions reported holding MAIA at the end of Q2 2026, together about 22% of the shares. See the largest owners.
Are MAIA insiders buying or selling?
In the last 12 months, MAIA insiders reported 25 open-market purchases worth $971K and no sales. The latest trade was on Sep 14, 2026. See every trade.
What is the short interest in MAIA?
As of Oct 30, 2026, 2.45M MAIA shares were sold short, 4.0% of the shares outstanding, down 2.8% from the report before. At the average daily volume of 271,949 shares, buying them all back would take about 9.0 trading days (days to cover). See the history.
Which famous investors hold MAIA?
3 of the 50 well-known investors we track reported MAIA in their latest 13F filing, including Jim Simons, Ken Griffin, Steve Cohen. The largest position is worth $471K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.